RxDoctor Payments Data

Ciara Jaro-Locke, APRN

Registered Nurse · Attleboro, MANPI 1245935139

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 28 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 7 manufacturers reported payments, led by AbbVie at 44.0% of the total.

$775in general payments, 2019–2025

Across 28 payments — averaging $27.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$341
  • Merz North America, Inc.$228
  • Neurocrine Biosciences, Inc.$59
  • Supernus Pharmaceuticals, Inc.$50
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$42
  • Indivior Inc.$29
  • plus $27 from 1 others

What the payments were for

  • Food & beverage$775100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$775 in reported general payments places this provider in the 85th percentile of 124 registered nurse providers in Massachusetts.

See all registered nurse providers in Massachusetts

Medicare billing

Part B allowed, 2024
$10,071
Medicare patients
26
Services billed
104

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl16$24,448
Aripiprazole20$2,119
Gabapentin20$643
Fluvoxamine Maleate12$637
Quetiapine Fumarate29$399
Mirtazapine34$359
Doxepin Hcl14$332
Prazosin Hcl23$316
Alprazolam21$292
Hydroxyzine Hcl15$236
Lamotrigine11$216
Trazodone Hcl23$207
Clonazepam12$120
Duloxetine Hcl15$116
Lorazepam12$79

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$341$24,44816 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 124 registered nurse providers in Massachusetts.

Other registered nurse in Attleboro

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →